Press coverage about Evoke Pharma (NASDAQ:EVOK) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evoke Pharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.8746091869217 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
EVOK has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Evoke Pharma in a research report on Tuesday, March 6th. ValuEngine downgraded shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, B. Riley restated a “buy” rating and issued a $5.00 price target (down from $10.00) on shares of Evoke Pharma in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Evoke Pharma presently has an average rating of “Buy” and an average target price of $7.71.
Evoke Pharma (EVOK) traded down $0.08 during trading on Tuesday, hitting $1.98. 41,358 shares of the stock were exchanged, compared to its average volume of 91,849. Evoke Pharma has a one year low of $1.85 and a one year high of $4.09. The company has a market cap of $31.92, a P/E ratio of -2.04 and a beta of 1.49.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.21. sell-side analysts expect that Evoke Pharma will post 0.1 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Evoke Pharma (EVOK) Stock Price” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.thestockobserver.com/2018/03/20/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-evoke-pharma-evok-stock-price.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.